Clinical trial

Integrase and Maraviroc Intensification in Neurocognitive Dysfunction (InMIND)

NCT02519777

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2016-04-21

PhasePHASE4

Study timeline

Study start (actual)2016-04-21Date precision: day

Registry last updated2022-04-22

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

HIV Infectionsunresolved

Interventions

Placebo for maraviroc (MVC)DRUG

Placebo for dolutegravir (DTG)DRUG

Dolutegravir (DTG)DRUG

Maraviroc (MVC)DRUG

Sponsors & collaborators

National Institute of Allergy and Infectious Diseases (NIAID)lead sponsor

Mapped research locations

New YorkNew York, United States2 HoustonTexas, United States1 ChicagoIllinois, United States1 Los AngelesCalifornia, United States1 PhiladelphiaPennsylvania, United States1 DallasTexas, United States1 BaltimoreMaryland, United States1 St LouisMissouri, United States1 NashvilleTennessee, United States1 SeattleWashington, United States1 ClevelandOhio, United States1 PittsburghPennsylvania, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02519777 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.